Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01FF10
|
| gptkbp:CASNumber |
1428935-60-7
|
| gptkbp:chemicalFormula |
C6400H9904N1728O1996S46
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:drugClass |
gptkb:monoclonal_antibody
|
| gptkbp:form |
solution for infusion
|
| gptkbp:genericName |
gptkb:durvalumab
|
| https://www.w3.org/2000/01/rdf-schema#label |
Imfinzi
|
| gptkbp:indication |
gptkb:non-small_cell_lung_cancer
gptkb:biliary_tract_cancer gptkb:extensive-stage_small_cell_lung_cancer |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
PD-L1 inhibitor
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionRequired |
https://www.imfinzi.com/
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
diarrhea
fatigue cough rash pneumonitis immune-mediated adverse reactions |
| gptkbp:target |
PD-L1
|
| gptkbp:bfsParent |
gptkb:AstraZeneca
|
| gptkbp:bfsLayer |
5
|